CN114206877A - 一种乌帕替尼的晶型及其制备方法和用途 - Google Patents
一种乌帕替尼的晶型及其制备方法和用途 Download PDFInfo
- Publication number
- CN114206877A CN114206877A CN202180004686.XA CN202180004686A CN114206877A CN 114206877 A CN114206877 A CN 114206877A CN 202180004686 A CN202180004686 A CN 202180004686A CN 114206877 A CN114206877 A CN 114206877A
- Authority
- CN
- China
- Prior art keywords
- csiv
- crystalline form
- csv
- crystal form
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 131
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 64
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 5
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 5
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims abstract description 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims abstract description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 62
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 26
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 230000005855 radiation Effects 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 11
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 11
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 11
- 229940011051 isopropyl acetate Drugs 0.000 claims description 11
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 11
- 239000012046 mixed solvent Substances 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 8
- 229910002483 Cu Ka Inorganic materials 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004113 Sepiolite Substances 0.000 claims description 6
- 150000002170 ethers Chemical class 0.000 claims description 6
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 6
- 150000002825 nitriles Chemical class 0.000 claims description 6
- 229910052624 sepiolite Inorganic materials 0.000 claims description 6
- 235000019355 sepiolite Nutrition 0.000 claims description 6
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 claims description 3
- 230000005496 eutectics Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 34
- 239000002136 L01XE07 - Lapatinib Substances 0.000 abstract description 11
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 abstract description 11
- 229960004891 lapatinib Drugs 0.000 abstract description 11
- 238000011161 development Methods 0.000 abstract description 5
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 1
- 238000005457 optimization Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 14
- 238000003860 storage Methods 0.000 description 13
- 230000008859 change Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 238000002411 thermogravimetry Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000002274 desiccant Substances 0.000 description 7
- 238000000113 differential scanning calorimetry Methods 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229910016860 FaSSIF Inorganic materials 0.000 description 4
- 229910005429 FeSSIF Inorganic materials 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 150000003330 sebacic acids Chemical class 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001757 thermogravimetry curve Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 229910017541 Cu-K Inorganic materials 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- RDYMFSUJUZBWLH-UHFFFAOYSA-N endosulfan Chemical compound C12COS(=O)OCC2C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl RDYMFSUJUZBWLH-UHFFFAOYSA-N 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229940126589 solid medicine Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了乌帕替尼的新晶型及其制备方法，含有该晶型的药物组合物，以及该晶型在制备JAK抑制剂药物和治疗类风湿性关节炎、克罗恩病、溃疡性结肠炎、异位性皮炎和银屑病关节炎药物中的用途。本发明提供的乌帕替尼晶型比现有技术具有一种或多种改进的特性，对未来该药物的优化和开发具有重要价值。
Description
PCT国内申请，说明书已公开。
Claims (17)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020105065563 | 2020-06-05 | ||
| CN202010506556 | 2020-06-05 | ||
| CN2020105348505 | 2020-06-12 | ||
| CN202010534850 | 2020-06-12 | ||
| PCT/CN2021/095103 WO2021244323A1 (zh) | 2020-06-05 | 2021-05-21 | 一种乌帕替尼的晶型及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114206877A true CN114206877A (zh) | 2022-03-18 |
| CN114206877B CN114206877B (zh) | 2024-04-19 |
Family
ID=78830708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180004686.XA Active CN114206877B (zh) | 2020-06-05 | 2021-05-21 | 一种乌帕替尼的晶型及其制备方法和用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114206877B (zh) |
| WO (1) | WO2021244323A1 (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112770756A (zh) * | 2018-09-29 | 2021-05-07 | 苏州科睿思制药有限公司 | 一种Upadacitinib的晶型及其制备方法和用途 |
| CN114380837A (zh) * | 2021-12-27 | 2022-04-22 | 上海邈金医药科技有限公司 | 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用 |
| CN117447481A (zh) * | 2023-12-23 | 2024-01-26 | 潍坊医学院 | 一种乌帕替尼-焦谷氨酸盐的无定形物及其制备方法与应用 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111909160B (zh) | 2019-05-09 | 2024-05-28 | 苏州鹏旭医药科技有限公司 | 一种乌帕替尼盐类化合物及其制备方法 |
| AU2021303629A1 (en) | 2020-07-08 | 2023-03-09 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of upadacitinib, preparation method therefor, and use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108368121A (zh) * | 2015-10-16 | 2018-08-03 | 艾伯维公司 | 制备(3S，4R)-3-乙基-4-(3H-咪唑并[1，2-a]吡咯并[2，3-e]吡嗪-8-基)-N-(2，2，2-三氟乙基)吡咯烷-1-甲酰胺及其固态形式的方法 |
| WO2020063939A1 (zh) * | 2018-09-29 | 2020-04-02 | 苏州科睿思制药有限公司 | 一种Upadacitinib的晶型及其制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2506716T3 (en) * | 2009-12-01 | 2017-09-04 | Abbvie Inc | HIS UNKNOWN TRICYCLIC RELATIONS |
| WO2018056269A1 (ja) * | 2016-09-20 | 2018-03-29 | 参天製薬株式会社 | Ｊａｋ阻害剤を含有する点眼剤 |
-
2021
- 2021-05-21 WO PCT/CN2021/095103 patent/WO2021244323A1/zh active Application Filing
- 2021-05-21 CN CN202180004686.XA patent/CN114206877B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108368121A (zh) * | 2015-10-16 | 2018-08-03 | 艾伯维公司 | 制备(3S，4R)-3-乙基-4-(3H-咪唑并[1，2-a]吡咯并[2，3-e]吡嗪-8-基)-N-(2，2，2-三氟乙基)吡咯烷-1-甲酰胺及其固态形式的方法 |
| WO2020063939A1 (zh) * | 2018-09-29 | 2020-04-02 | 苏州科睿思制药有限公司 | 一种Upadacitinib的晶型及其制备方法和用途 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112770756A (zh) * | 2018-09-29 | 2021-05-07 | 苏州科睿思制药有限公司 | 一种Upadacitinib的晶型及其制备方法和用途 |
| CN114380837A (zh) * | 2021-12-27 | 2022-04-22 | 上海邈金医药科技有限公司 | 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用 |
| CN117447481A (zh) * | 2023-12-23 | 2024-01-26 | 潍坊医学院 | 一种乌帕替尼-焦谷氨酸盐的无定形物及其制备方法与应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021244323A1 (zh) | 2021-12-09 |
| CN114206877B (zh) | 2024-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114206877B (zh) | 一种乌帕替尼的晶型及其制备方法和用途 | |
| JP7199739B2 (ja) | Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態 | |
| CN109153656B (zh) | 他发米帝司葡甲胺盐的晶型e及其制备方法和用途 | |
| CN114929671B (zh) | 化合物i二盐酸盐的共晶及其制备方法和用途 | |
| WO2022121670A1 (zh) | Tolebrutinib的晶型及其制备方法和用途 | |
| WO2022170864A1 (zh) | Belumosudil甲磺酸盐的晶型及其制备方法和用途 | |
| WO2015014315A1 (zh) | 一种抑制剂的晶型及其制备方法和用途 | |
| CN114206878B (zh) | 乌帕替尼的晶型及其制备方法和用途 | |
| CN112888692A (zh) | 一种Upadacitinib的晶型及其制备方法和用途 | |
| WO2023040513A1 (zh) | Amg510化合物的晶型及其制备方法和用途 | |
| WO2018006870A1 (zh) | Galunisertib的晶型及其制备方法和用途 | |
| CN112770756A (zh) | 一种Upadacitinib的晶型及其制备方法和用途 | |
| CN114907325A (zh) | Belumosudil甲磺酸盐的晶型及其制备方法和用途 | |
| CN114773342A (zh) | Mrtx849化合物的晶型及其制备方法和用途 | |
| CN114163453A (zh) | 一种洛普替尼晶型及其制备方法 | |
| WO2023193563A1 (zh) | 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物 | |
| CN114787154A (zh) | 一种Deucravacitinib的晶型及其制备方法和用途 | |
| KR20030081424A (ko) | 피리미딘 뉴클레오시드 유도체의 결정 | |
| WO2018024236A1 (zh) | 一种jak1选择性抑制剂的新晶型及其制备方法和用途 | |
| CN115073430A (zh) | Belumosudil甲磺酸盐的晶型及其制备方法和用途 | |
| US10815232B2 (en) | Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof | |
| WO2017215521A1 (zh) | Plx3397的盐酸盐晶型及其制备方法和用途 | |
| CN113583027A (zh) | Risdiplam晶型及其制备方法和用途 | |
| WO2019105217A1 (zh) | Galunisertib的晶型及其制备方法和用途 | |
| WO2019137027A1 (zh) | Galunisertib的晶型及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |